Extracorporeal Membrane Oxygenation (ECMO) Systems Market Analysis Report 2031

Coverage: Extracorporeal Membrane Oxygenation (ECMO) Systems Market covers analysis By Modality (Veno-Arterial (VA), Veno-Venous (VV), and Others), Application (Respiratory and Cardiology), Patient Type (Adult, Pediatric, and Neonatal), and End User (Hospitals and Clinics, Cardiac Centers, Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)

Publication Month : Mar 2024

  • Report Code : TIPRE00020839
  • Category : Medical Device
  • Status : Upcoming
  • No. of Pages : 150
Inquire Before Buy




[Research Report] The Extracorporeal Membrane Oxygenation (ECMO) Systems Market Size is expected to grow from US$ 550.68 million in 2022 to US$ 800.03 million by 2030; it is estimated to register the growth rate of 4.8% over the forecast period.

Market Insights and Analyst View:

Extracorporeal Membrane Oxygenation (ECMO) Systems are life support machines that are used to provide temporary assistance to severe respiratory or cardiac failure patients. The ECMO system works by removing blood from the patient’s body, oxygenating it outside of the body, and then returning it to the patient. These systems are used as a last resort when other treatments have failed. They are commonly employed in intensive care units and require specialized training and expertise to operate. ECMO Systems does not cure lung or heart damage; it just takes the load from the lungs and heart, which gives time for the organs to recover during treatment. The increasing prevalence of respiratory and cardiovascular conditions, along with the increase in cardiovascular surgeries among the geriatric population, is expected to drive the ECMO systems market. Moreover, increased use of ECMO systems among neonatal and pediatric patients is expected to create ample opportunities in the ECMO systems market growth.

Growth Drivers and Challenges:

Cardiopulmonary disorders are mainly affecting the lungs and heart of people. These conditions are classified as chronic obstructive pulmonary disease (COPD) and cardiovascular diseases. Cardiovascular diseases comprise blood vessel diseases, heart arrhythmia problems, coronary artery diseases, and heart defects that affect the blood vessels and heart. Further, COPD consists of chronic bronchitis and emphysema.

As per the American Lung Association, COPD is the prominent cause of death in the US, affecting ~12 million Americans in 2022. According to the WHO, COPD will be the third leading cause of death globally in 2021. The high COPD mortality rate is linked to acute exacerbations that cause failure of respiratory muscles, resulting in the loss of ability to breathe independently, which leads to death from systemic infection and asthma. Further, as per the Burden of Obstructive Lung Disease (BOLD) report, 2020, COPD mortality is projected to rise worldwide over the next 40 years, reaching 5.4 million deaths annually by 2060. Thus, with the rising incidence of COPD, the demand for ECMO systems is also on the rise.

As per the Global Health Data Exchange registry, the worldwide prevalence of congestive heart failure is 64.34 million cases in 2023. The primary risk factors of CVDs include ethnicity, family history, and age; other risk factors include hypertension, obesity, tobacco consumption, high cholesterol, physical inactivity, and diabetes. The WHO estimates that 17.9 million lives are lost due to CVDs annually. Oxygenator devices can be a key assistance to doctors to reduce the mortality rate. In the event of heart failure, the blood oxygen level is maintained with the assistance of an external device, as the heart is unable to maintain proper oxygen levels. Oxygenator devices are used to manage patients with heart failure.

Therefore, the rising prevalence of cardiopulmonary diseases (cardiovascular disorders and COPD) boosts the demand for ECMO systems.

However, there are various risk factors associated with the use of ECMO systems that can affect the patient's condition. Bleeding is one of the risk factors experienced among most of the patients with ECMO systems due to the use of anti-coagulant. Additionally, increased risk of stroke, infections, kidney failure, mechanical failure, and others are also observed in some of the cases, which is likely to hamper the ECMO systems market growth.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Extracorporeal Membrane Oxygenation (ECMO) Systems Market: Strategic Insights

Analyst Image


Have a question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Analyst Image  Speak to Analyst

Report Segmentation and Scope:

The “Global ECMO Systems Market Size” is segmented based on modality, application, patient type, end user, and geography. Based on modality, the ECMO systems market is segmented into veno-arterial (VA), veno-venous (VV), and others. Based on application, the ECMO systems market is bifurcated into respiratory and cardiology. Based on patient type, the ECMO systems market is segmented into adult, pediatric, and neonatal. Based on end users, the ECMO systems market is categorized into hospitals and Clinics, cardiac centers, and others. The ECMO systems market based on geography is fragmented into North America (US, Canada, and Mexico), Europe (Germany, France, Italy, UK, Russia, and Rest of Europe), Asia Pacific (Australia, China, Japan, India, South Korea, and Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, UAE, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).

  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
  • Request discounts available for Start-Ups & Universities

Segmental Analysis:

Based on modality, the ECMO systems market size is segmented into veno-arterial (VA), veno-venous (VV), and others. In 2022, the veno-arterial segment held the largest share of the market and is expected to register the fastest rate during the coming years owing to the increased effectiveness and reliability of gas exchange along with widespread use among cardiac arrest patients as it helps with algorithm life support techniques to reestablish blood flow.

ECMO Systems Market, by Modality – 2022 and 2030

  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
  • Request discounts available for Start-Ups & Universities

Based on application, the ECMO systems market is bifurcated into respiratory and cardiology. In 2022, the respiratory segment held the largest market share and is also expected to grow at the fastest rate during the coming years, owing to the increasing prevalence of respiratory disorders along with smoking and tobacco use, which can cause respiratory failure.

Based on patient type, the ECMO systems market is segmented into adult, pediatric, and neonatal. In 2022, the adult segment held the largest share of the market by patient type. However, the neonatal segment is expected to register the highest growth rate during the coming years owing to the increasing prevalence of respiratory conditions such as pneumonia, respiratory distress syndrome, and others among the neonatal population.

Based on end users, the ECMO systems market is categorized into hospitals and clinics, cardiac centers, and others. In 2022, the hospital and clinics segment held the major market share and is expected to register a significant growth rate during the coming years, owing to the increasing hospital admissions for respiratory conditions to receive treatment and care for the required duration.

Regional Analysis:

The ECMO systems market encompasses five key regions: North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa. In 2022, North America held the largest ECMO systems market share, closely followed by Europe, and Asia Pacific is estimated to register the highest CAGR during the forecast period. The major growth factor for the North American market is the rising prevalence of cardiovascular and respiratory disorders in the region. It has increased the incidence of cardiopulmonary disorders such as COPD, chronic bronchitis, congestive heart failure, and others. According to the American Lung Association, there were ~12.5 million people diagnosed with chronic bronchitis, COPD, and emphysema in the US in 2020.

Additionally, the rising incidence and prevalence of these disorders have increased the count of surgical procedures among large patient populations, which has fueled the growth of the ECMO systems market. For instance, in the Lifespan health system study, there were ~500,00 open heart surgeries performed every year in the US. Additionally, the rising prevalence of respiratory failure and infectious diseases is further expected to create demand for ECMO systems.

Furthermore, the increasing prevalence of CVDs is the leading cause of death on the global level, and ECMO systems can be of great assistance in lifesaving in emergencies. As per the WHO, ~17.9 million lives are lost due to CVD every year, and favorable reimbursement policies are also likely to create ample opportunities for the growth of ECMO systems. Therefore, the increasing prevalence and prevalence of cardiopulmonary disorders are expected to lead to the growth of the ECMO systems market during the forecast period.

However, Asia Pacific is registered as the fastest-growing region in the global ECMO systems market. The market in this region is expected to increase significantly in countries such as China, Japan, and India. The market's growth is attributed to the increasing focus of market players in developing economies and supportive government policies. Although the availability of effective and safe prevention strategies worldwide, cardiovascular disease (CVD) remains the leading cause of death and premature death globally. The growth of the market is mainly attributed to the increasing prevalence of atrial fibrillation (AF) in China, the increasing burden of various other heart diseases, and the rising geriatric population across the region are all expected to support market growth. As per the prediction done by the World Heart Federation, cardiovascular events like ischemic heart disease and stroke are expected to rise by 50% among the Chinese population between 2010 and 2030. The Indian Heart Association stated that 50% of heart attacks occur under the age of 50, while 25% of heart attacks occur under 25 years of age. Both the male and female populations in the country equally exhibit the risk of developing heart disease.

Moreover, stroke is one of atrial fibrillation's frequent and devastating complications. About one-third of the patients with atrial fibrillation are asymptomatic, and atrial fibrillation may go undetected in the patients until symptoms develop. As the oxygenator supplies oxygen, by removing carbon dioxide, to the artery during heart surgeries, the heart is relieved from performing pumping duties. Thus, the growing prevalence of cardiovascular disease in the region is fueling the demand for the ECMO systems market.

According to the Frontier Media Public Health report published in June 2022, the most recent Chinese national survey of COPD showed that China accounted for almost 25% of all COPD cases globally. As compared with the survey results ten years ago, the prevalence of COPD has increased by 67% in the aged 40 years or older group and has reached epidemic proportions. Moreover, the beginning of the COVID-19 pandemic in Wuhan City in China led to the development of severe acute respiratory syndrome among the large population, which in turn created the demand for the ECMO systems market. Moreover, during the COVID-19 pandemic, India was the second most affected country in the region, with the second highest number of cases with different waves of COVID-19, which has raised the growth of the ECMO systems market.

Therefore, the growing prevalence of cardiovascular as well as respiratory diseases in the population of Asia Pacific is fueling the demand for ECMO systems.

Industry Developments and Future Opportunities:

Various initiatives taken by key players operating in the global ECMO systems market are listed below:

  1. In January 2023, Chinabridge Medical officially launched the first domestically developed extracorporeal membrane oxygenation (ECMO) machine that will help in the treatment of COVID-19 patients in critical condition and boost the development of the country's high-end medical devices. National Medical Products Administration approves it for emergency use within China.
  2. In November 2022, LivaNova PLC was granted US Food and Drug Administration (FDA) 510(k) for extracorporeal membrane oxygenation (ECMO), LifeSPARC. LivaNova leveraged existing real-world evidence, inclusive of data collected during the COVID-19 pandemic, to receive this new indication.
  3. In February 2020, Fresenius Medical Care's Novalung was approved by the FDA for the treatment of acute respiratory or cardiopulmonary failure. Novalung is the first extracorporeal membrane oxygenation (ECMO) system to be cleared for more than six hours of use as extracorporeal life support.

Competitive Landscape and Key Companies:

Some of the major players operating in the global ECMO systems market include LivaNova (Alung Technologies Inc.), Eurosets, Getinge AB, Medtronic PLC, Microport Scientific Corporation, Inspira Technologies, Terumo Medical Corporation, Abbott Laboratories, Fresenius Medical Care Company (Xenios AG), and Chinabridge Medical among others. These companies focus on geographical expansions, new product launches, strategic collaboration, and product approval to meet the growing consumer demand worldwide and increase their product range in specialty portfolios. They have a widespread global presence, which allows them to serve a large set of customers and subsequently increase their market share.

Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

The List of Companies

1. Getinge Group
2. Medtronic plc
3. LivaNova PLC
5. Terumo Corporation
6. MicroPort Scientific Corporation
7. NIPRO Corporation
8. OriGen Biomedical, Inc.
9. ALung Technologies, Inc.
10. EUROSETS S.r.l
11. MAQUET Holding B.V. & Co. KG
12. Sorin Group
13. Medos Medizintechnik AG
14. Abbott Laboratories
15. Braile Biomedical
16. Edwards Lifesciences Corp
17. Elsius Biomedical Inc.
18. Spectrum Medical

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • 3.1 Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • 3.2 Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • 3.3 Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • 3.4 Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Trends and growth analysis reports related to Extracorporeal Membrane Oxygenation (ECMO) Systems Market